COVID-19 Vaccines Authorized in the United States
	Pfizer-BioNTech		Moderna	Janssen (J&J)
Vaccine type	mRNA		mRNA	viral vector
Authorized age groups	5 – 11 years	≥12 years	≥ 18 years	≥ 18 years
Number of doses in initial series	2	2	2	1
Interval between doses in initial series	21 days	21 days	28 days	n/a
Dose volume	0.2 mL pediatric formula	0.3 mL	0.5 mL	0.5 mL
FDA status	Emergency Use Authorization	Approved	Emergency Use Authorization	Emergency Use Authorization
Individuals may receive influenza and any other vaccines at the same time as a COVID-19 vaccine.
	Pfizer-BioNTech		Moderna	Janssen (J&J)
Authorized booster	yes		yes	yes
Interval between initial series and booster	6 months		6 months	2 months
Dose volume	0.3 mL		0.25 mL	0.5
Individuals qualifying for booster	≥ 16 years old		≥ 18 years old	≥ 18 years old
FDA status	Emergency Use Authorization		Emergency Use Authorization	Emergency Use Authorization
Heterologous (or "mix and match") booster doses are allowed following the eligibility requirements of the individual’s primary COVID-19 vaccine.
	Pfizer-BioNTech		Moderna	Janssen (J&J)
Authorized 3rd dose	yes		yes	n/a
Interval between initial series and 3rd dose	28 days		28 days	n/a
Dose volume	0.3 mL		0.5 mL	n/a
Individuals qualifying for 3rd dose	≥12 years		≥ 18 years	n/a
	Moderate or severely immunocompromised individuals:		Moderate or severely immunosuppressed individuals:	n/a
	Receiving active cancer treatment for tumors or cancers of the blood		Receiving active cancer treatment for tumors or cancers of the blood
	Received an organ transplant and are taking medicine to suppress the immune system		Received an organ transplant and are taking medicine to suppress the immune system
	Received a stem cell transplant within the last two years or are taking medicine to suppress the immune system		Received a stem cell transplant within the last two years or are taking medicine to suppress the immune system
	Have moderate or severe primary immunodeficiency (such as DiGeorge syndrome or Wiskott-Aldrich syndrome)		Have moderate or severe primary immunodeficiency (such as DiGeorge syndrome or Wiskott-Aldrich syndrome)
	Have advanced HIV infection (high viral load or low CD4 count)or untreated HIV infection		Have advanced HIV infection (high viral load or low CD4 count)or untreated HIV infection
	Active treatment with high-dose corticosteroids or other drugs that may suppress immune response		Active treatment with high-dose corticosteroids or other drugs that may suppress immune response
FDA status	Emergency Use Authorization		Emergency Use Authorization	n/a
Additional 3rd doses should be the same vaccine type as the individual’s primary COVID-19 vaccine if available.